Drugs / Liposomal daunorubicin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02724163 | Apr 2016 → Dec 2031 expected | acute myeloid leukemia | University of Birmingham | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03860844 Background | Aug 2019 → Sep 2022 | acute lymphoblastic leukemia, acute myeloid leukemia | Sanofi | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposomal daunorubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02724163 ↗ |
| Modality | Small molecule | “Anthracycline” NCT02724163 ↗ |
| Route | Intravenous | “1 hour IV infusion” NCT02724163 ↗ |